SCHEMBL4809281

SCHEMBL4809281

CC(F)c1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 15/20 0.70
CA12 O43570 5/20 0.70
CA1 P00915 5/20 0.70
CA2 P00918 5/20 0.70
CA9 Q16790 5/20 0.70
MT-CO2 P00403 3/20 0.70
PTGS1 P23219 2/20 0.70
LMNA P02545 1/20 0.70
CA3 P07451 1/20 0.70
ADRB2 P07550 1/20 0.70
ADRB1 P08588 1/20 0.70
CYP3A4 P08684 1/20 0.70
ADORA3 P0DMS8 1/20 0.70
CHRM1 P11229 1/20 0.70
ADRA2B P18089 1/20 0.70
CA4 P22748 1/20 0.70
CA6 P23280 1/20 0.70
SLC6A2 P23975 1/20 0.70
PDE4A P27815 1/20 0.70
ADORA1 P30542 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4891512 0.90 PTGS2 (0.70) PTGS2CA12CA1CA2CA9
SCHEMBL214781 0.90 PTGS2 (0.66) PTGS2CA12CA1CA2CA9
SCHEMBL5983421 0.89 PTGS2 (0.68) PTGS2CA12CA1CA2CA9
SCHEMBL4884123 0.85 PTGS2 (0.64) PTGS2CA12CA1CA2CA9
SCHEMBL6169802 0.83 PTGS2 (0.61) PTGS2CA12CA1CA2CA9
Valdecoxib SCHEMBL3853130 0.83 PTGS2 (1.00) PTGS2CA12CA1CA2CA9
Valdecoxib SCHEMBL3356 0.83 PTGS2 (1.00) PTGS2CA12CA1CA2CA9
SCHEMBL6168344 0.83 PTGS2 (1.00) PTGS2CA12CA1CA2CA9
Valdecoxib SCHEMBL5998054 0.82 PTGS2 (0.88) PTGS2CA12CA1CA2CA9
Valdecoxib SCHEMBL6601157 0.82 PTGS2 (0.97) PTGS2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003089013-A1 CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-10-30 WO claimed
US-7329401-B2 Cyclooxygenase-2 selective agents useful as imaging probes and related methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-02-12 US disclosed
US-20070286801-A1 CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2007-12-13 US disclosed
WO-2003089013-A1 CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070286801-A1 CYCLOOXYGENASE-2 SELECTIVE AGENTS USEFUL AS IMAGING PROBES AND RELATED METHODS PTGS2, PTGES2, PTGER2 PTGS2 1/4885CA12 1801/4885CA1 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.